TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2026

Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial.

Matthew Matasar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.